Mr. Chairman, the assertion that the amendment will lead to slowing new discoveries and discourage more pharmaceutical innovation has to be answered. The argument is basically, I believe, a defense of high profits. Developing countries are so poor, however, that no pharmaceutical company can logically depend on profits earned in Africa to fund research. It has been also mentioned that the WTO agreement on trade aspects of intellectual property already contains a humanitarian exception for health and other emergencies, so therefore, this amendment would not be needed. However, the United States brought a WTO case against Brazil, nonetheless. The TRIPS agreement was agreed to by the U.S. in 1995, while the U.S. case against Brazil was launched in June, 2000. Clearly, the exception is not enough, and congressional action is needed. I know the gentleman from Virginia is a caring person, and we are all caring people here.
Editor's note · Context
Addressing concerns about pharmaceutical innovation and the impact of WTO agreements on developing countries.
Share
More from Dennis Kucinich
What I would like to do, Mr. Chairman, is to present to you and the ranking member reports that have been forwarded to me regarding these casualties. Maybe these are reports that you've seen, and maybe they aren't; but I certainly think…
The releases from power plants and industrial boilers represent today roughly a quarter of the mercury releases to the atmosphere.
Over 12 million Americans are unemployed while our infrastructure is falling apart. But at least the U.S. is creating some jobs--for spies. The Washington Post says the Pentagon will dramatically expand the role and size of its own…
Neil Armstrong's voyage to the Moon represented a personal heroic journey, and it was also expressive of a uniquely American capability and capacity to reach higher and higher, to expand our horizons, to seek newer worlds, and to do that…





